Tolnaftate for yeast infection

Tolnaftate skin cream, gel, solution, or spray

What is this medicine?

TOLNAFTATE (tole NAF tate) is an antifungal medicine. It is used to treat certain kinds of fungal or yeast infections of the skin.

This medicine may be used for other purposes; ask your health care provider or pharmacist if you have questions.

COMMON BRAND NAME(S): Absorbine Athletes Foot, Absorbine Jr. Antifungal, Aftate For Athletes Foot, Aftate for Jock Itch, Fungi-Guard, Lamisil AF, Q-Naftate, Termin8, Tinactin, Tinactin Jock Itch, Tinaderm, Ting Antifungal

What should I tell my health care provider before I take this medicine?

They need to know if you have any of these conditions:

  • diabetes

  • immune system problems

  • peripheral vascular disease

  • an unusual or allergic reaction to tolnaftate, other medicines, foods, dyes, or preservatives

  • pregnant or trying to get pregnant

  • breast-feeding

How should I use this medicine?

This medicine is for external use only. Do not take by mouth. Avoid getting in the eyes or nose. Follow the directions on the label. Wash hands before and after use. If treating hands, only wash hands before use. Cleanse and dry affected area thoroughly. Apply a thin layer of the product to cover the affected skin and surrounding area. You can cover the area with a sterile gauze dressing (bandage). Do not use an airtight bandage (such as a plastic-covered bandage). Use in the morning and evening or as directed by your doctor or health care professional. Use this medicine for the full amount of time recommended on the package or by your doctor or health care professional even if you begin to feel better. Do not use for more than 4 weeks without advice.

Talk to your pediatrician regarding the use of this medicine in children. While this medicine may be prescribed for children as young as 2 years for selected conditions, precautions do apply.

Overdosage: If you think you have taken too much of this medicine contact a poison control center or emergency room at once.

NOTE: This medicine is only for you. Do not share this medicine with others.

What if I miss a dose?

If you miss a dose, use it as soon as you can. If it is almost time for your next dose, use only that dose. Do not use double or extra doses.

What may interact with this medicine?

Interactions are not expected. Do not use any other skin products on the affected area without asking your doctor or health care professional.

This list may not describe all possible interactions. Give your health care provider a list of all the medicines, herbs, non-prescription drugs, or dietary supplements you use. Also tell them if you smoke, drink alcohol, or use illegal drugs. Some items may interact with your medicine.

What should I watch for while using this medicine?

Tell your doctor or healthcare professional if your symptoms do not start to get better or if they get worse. You may have a skin infection that does not respond to this medicine.

If you are using this medicine for ‘jock itch’ be sure to dry the groin completely after bathing. Do not wear underwear that is tight-fitting or made from synthetic fibers like rayon or nylon. Wear loose-fitting, cotton underwear.

If you are using this medicine for athlete’s foot be sure to dry your feet carefully after bathing, especially between the toes. Do not wear socks made from wool or synthetic materials like rayon or nylon. Wear clean cotton socks and change them at least once a day, change them more if your feet sweat a lot. Also, try to wear sandals or shoes that are well-ventilated.

What side effects may I notice from receiving this medicine?

Side effects that you should report to your doctor or health care professional as soon as possible:

  • allergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue

  • increased inflammation, redness, or pain at the affected area

Side effects that usually do not require medical attention (report to your doctor or health care professional if they continue or are bothersome):

  • dry skin

  • mild skin irritation, burning, or itching at the affected area

This list may not describe all possible side effects. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Where should I keep my medicine?

Keep out of the reach of children.

Store at room temperature between 15 and 30 degrees C (59 and 86 degrees F). Do not freeze. Throw away any unused medicine after the expiration date. Some gels, solutions or sprays may contain alcohol or have other flammable components. Do not use while smoking or near heat or flame.

NOTE: This sheet is a summary. It may not cover all possible information. If you have questions about this medicine, talk to your doctor, pharmacist, or health care provider.

Share Facebook Twitter LinkedIn Email Get useful, helpful and relevant health + wellness information enews

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Tolnaftate topical

Generic Name: tolnaftate topical (toll NAF tate)
Brand Name: Absorbine Athletes Foot, Absorbine Jr. Antifungal, Blis-To-Sol, Clarus Antifungal, Fungi-Guard, LamISIL Defense, Mycocide NS, Tinactin, Tinaderm, Tinaspore, …show all 29 brand namesGenaspor, NP 27, Tinactin Jock Itch, Ting, Aftate For Athletes Foot, Aftate For Jock Itch, Absorbine Jock Itch, Fungatin, Hongos, Q-Naftate, Podactin, T-Athlete, Desenex Spray, Tinactin Deodorant Spray, Dr Scholl’s Odor Destroyers Sport Spray, LamISIL AT Defense, LamISIL AT Defense Cream to Powder, Athlete’s Foot Antifungal Liquid, Fungoid-D

Medically reviewed by Drugs.com on Dec 4, 2019 – Written by Cerner Multum

  • Overview
  • Side Effects
  • Dosage
  • Professional
  • Pregnancy
  • More

What is tolnaftate topical?

Tolnaftate is an antifungal medication that fights infections caused by fungus.

Tolnaftate topical (for the skin) is used to treat infections such as athlete’s foot (tinea pedis), jock itch (tinea cruris), and ringworm (tinea corporis). Tolnaftate is also used with other antifungals to treat infections of the nails, scalp, palms, and soles of the feet.

Tolnaftate topical may also be used for purposes not listed in this medication guide.

Important Information

Follow all directions on your medicine label and package. Tell each of your healthcare providers about all your medical conditions, allergies, and all medicines you use.

Before taking this medicine

You should not use tolnaftate topical if you are allergic to it.

Ask a doctor or pharmacist if it is safe for you to use tolnaftate topical if you have other medical conditions.

It is not known whether tolnaftate topical will harm an unborn baby. Do not use this medicine without a doctor’s advice if you are pregnant.

It is not known whether tolnaftate topical passes into breast milk or if it could harm a nursing baby. Do not use this medicine without a doctor’s advice if you are breast-feeding a baby.

Do not give this medicine to a child without medical advice.

How should I use tolnaftate topical?

Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.

Do not take by mouth. Tolnaftate topical is for use only on the skin. Do not use this medicine on open wounds or on sunburned, windburned, dry, chapped, or irritated skin. If this medicine gets in your eyes, nose, mouth, rectum, or vagina, rinse with water.

Do not cover the treated skin area with a bandage that does not allow air circulation. You may use a light cotton-gauze dressing to protect your clothing over treated skin areas.

Wash your hands before and after applying this medicine, unless you are using it to treat a skin condition on your hands.

Clean and dry the skin before you apply tolnafate topical.

Call your doctor if your symptoms do not improve, or if they get worse.

Store at room temperature away from moisture and heat. Keep the tube tightly closed when not in use.

What happens if I miss a dose?

Apply the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next dose. Do not use extra medicine to make up the missed dose.

What happens if I overdose?

An overdose of tolnaftate topical is not expected to be dangerous. Seek emergency medical attention or call the Poison Help line at 1-800-222-1222 if anyone has accidentally swallowed the medication.

What should I avoid while using tolnaftate topical?

Rinse with water if tolnaftate topical gets in your eyes.

Avoid tight-fitting synthetic clothing that does not allow air circulation. Wear loose-fitting clothing made of cotton and other natural fibers until your infection is healed.

Tolnaftate topical side effects

Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Stop using tolnaftate topical and call your doctor at once if you have skin irritation after applying this medicine.

Common side effects may include mild itching, dryness, or peeling of treated skin.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Tolnaftate topical dosing information

Usual Adult Dose for Tinea Corporis:

Apply to the affected area once or twice a day for 2 to 4 weeks.

Usual Adult Dose for Tinea Cruris:

Apply to the affected area once or twice a day for 2 to 4 weeks.

Usual Adult Dose for Tinea Pedis:

Apply to the affected area once or twice a day for 2 to 4 weeks.

Usual Adult Dose for Tinea Versicolor:

Apply to the affected area once or twice a day for 2 to 4 weeks.

Usual Pediatric Dose for Tinea Corporis:

2 years or older: Apply to the affected area once or twice a day for 2 to 4 weeks.

Usual Pediatric Dose for Tinea Cruris:

2 years or older: Apply to the affected area once or twice a day for 2 to 4 weeks.

Usual Pediatric Dose for Tinea Pedis:

2 years or older: Apply to the affected area once or twice a day for 2 to 4 weeks.

Usual Pediatric Dose for Tinea Versicolor:

2 years or older: Apply to the affected area once or twice a day for 2 to 4 weeks.

What other drugs will affect tolnaftate topical?

It is not likely that other drugs you take orally or inject will have an effect on topically applied tolnaftate. But many drugs can interact with each other. Tell each of your health care providers about all medicines you use, including prescription and over-the-counter medicines, vitamins, and herbal products.

Further information

Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use this medication only for the indication prescribed.

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Copyright 1996-2018 Cerner Multum, Inc. Version: 4.01.

Medical Disclaimer

More about tolnaftate topical

  • Side Effects
  • During Pregnancy or Breastfeeding
  • Dosage Information
  • Pricing & Coupons
  • En Español
  • 6 Reviews
  • Drug class: topical antifungals

Consumer resources

  • Tolnaftate Cream and Solution
  • Tolnaftate Powder
  • Tolnaftate Spray and Spray Powder
  • Tolnaftate Topical (Advanced Reading)

Other brands: Tinactin, Absorbine Jr Antifungal, Absorbine Athlete’s Foot, Aftate, … +12 more

Professional resources

  • Tolnaftate (AHFS Monograph)
  • … +1 more

Related treatment guides

  • Tinea Cruris
  • Tinea Pedis
  • Tinea Versicolor
  • Tinea Corporis

Antifungal – Formula 3® Professional

  • Odorless
  • Will not stain
  • Absorbed in seconds
  • Requires no drying time
  • Residue free – no removal or cleaning required
  • Will not blacken the nail
  • Conditions the nail and skin

Formula 3® is applied twice daily, morning and night with an applicator brush, to all affected nails and immediately adjacent skin. Daily application is required for a period usually ranging from 3-6 months, depending upon the degree of involvement, until such time as the patient has grown out a new, full, healthy nail. Weekly trimming by the patient, professional removal of the unattached nail, and debridement is suggested.

Formula 3® is backed by an unconditional, patient direct, money back guarantee. Simply call the 800 number on the bottle for a full refund if you are not completely satisfied.

Tolnaftate, long approved by the FDA and universally accepted for its safety and efficacy, is now available in oil soluble form for topical treatment of nail fungus.

Questions and Answers about Formula 3 Antifungal

Is Formula 3 FDA Approved?

Tolnaftate, the active ingredient in Formula 3, has been FDA approved for over 50 years. Tetra Corporation’s proprietary technology makes Tolnaftate oil soluble.

What is Tolnaftate

Tolnaftate is an antifungal agent used to treat fungal infections on the skin and foot such as ringworm, jock itch and athlete’s foot. Tolnaftate was synthesized in the early 1950’s by Japanese scientists and was approved as an over-the-counter drug by the U.S. Food and Drug Administration in 1965. Until Formula 3 was developed, Tolnaftate was insoluble in oil or water and was emulsified in all medications.

How is Formula 3 different than all the other products that use Tolnaftate 1% as the active ingredient?
Formula 3 is the only oil-based treatment available. It requires no drying time, is odorless, does not stain or leave any residue.

What makes Formula 4 so effective?
Jojoba oil moves the Tolnaftate to the affected area. Jojoba oil is an all natural oil. It is virtually identical to the sebum produced by our sebaceous glands. In other words, it’s very similar to the oil your skin produces naturally.

How long does it take to dry?
Formula 3 is an oil and is absorbed in seconds. In addition, it is odorless, does not stain, and leaves no residue.

Any skin sensitivity associated with the use of Formula 3?
The oils in Formula 3 actually condition the skin. It is extremely rare to have a hypersensitivity to Tolnaftate which may result in a minor skin irritation. Simply stop treatment and the skin will clear. See your doctor if the condition persists.

What if I am allergic to nuts; any precautions?
Nut allergies are a reaction to the essential oils of the nut. Formula 3 contains no essential oils.

Can pregnant women use Formula 3?
Tolnaftate has a pregnancy rating of Category C.

How long do I need to wait to wash so as not to remove or compromise the application?
Formula 3 is absorbed within seconds of contact. Once applied, you do not need to wait to wash or resume your normal routine.

How many times a day do I need to apply Formula 3?
Twice. Morning and evening, before bedtime.

How long will a bottle of Formula 3 last?
It depends on the size of the area that is being treated, but usually around 3-6 months.

When is the best time to apply Formula 3 in the morning; before or after a shower?
It is better to apply Formula 3 after showering when the skin has more capacity for absorption. It should be noted that virtually equal results were achieved with before-shower applications.

Have there been any side effects?
There is no evidence of side effects associated with the use of Formula 3. A very small percentage of patients have developed sensitivity to Tolnaftate as evidenced by very minor skin irritation and redness.

What is the shelf life of Formula 3?
5 years.

This information is provided to you by the doctors of the LakeForest Foot and Ankle Center.
Call 301-948-3668 for an appointment.

Lamisil

WARNINGS

Included as part of the PRECAUTIONS section.

PRECAUTIONS

Hepatotoxicity

Cases of liver failure, some leading to liver transplant or death, have occurred with the use of Lamisil Tablets in individuals with and without preexisting liver disease.

In the majority of liver cases reported in association with use of Lamisil Tablets, the patients had serious underlying systemic conditions. The severity of hepatic events and/or their outcome may be worse in patients with active or chronic liver disease. Treatment with Lamisil Tablets should be discontinued if biochemical or clinical evidence of liver injury develops.

Lamisil Tablets are not recommended for patients with chronic or active liver disease. Before prescribing Lamisil Tablets, liver function tests should be performed since hepatotoxicity may occur in patients with and without pre-existing liver disease. Periodic monitoring of liver function tests is recommended. Lamisil should be immediately discontinued in case of elevation of liver function tests. Patients prescribed Lamisil Tablets should be warned to report immediately to their physician any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain or jaundice, dark urine, or pale stools. Patients with these symptoms should discontinue taking oral terbinafine, and the patient’s liver function should be immediately evaluated.

Taste Disturbance Including Loss of Taste

Taste disturbance, including taste loss, has been reported with the use of Lamisil Tablets. It can be severe enough to result in decreased food intake, weight loss, anxiety, and depressive symptoms. Taste disturbance may resolve within several weeks after discontinuation of treatment, but may be prolonged (greater than 1 year), or may be permanent. If symptoms of a taste disturbance occur, Lamisil Tablets should be discontinued.

Smell Disturbance Including Loss Of Smell

Smell disturbance, including loss of smell, has been reported with the use of Lamisil Tablets. Smell disturbance may resolve after discontinuation of treatment, but may be prolonged (greater than 1 year), or may be permanent. If symptoms of a smell disturbance occur, Lamisil Tablets should be discontinued.

Depressive Symptoms

Depressive symptoms have occurred during postmarketing use of Lamisil Tablets. Prescribers should be alert to the development of depressive symptoms, and patients should be instructed to report depressive symptoms to their physician.

Hematologic Effects

Transient decreases in absolute lymphocyte counts (ALCs) have been observed in controlled clinical trials. In placebo-controlled trials, 8/465 subjects receiving Lamisil Tablets (1.7%) and 3/137 subjects receiving placebo (2.2%) had decreases in ALC to below 1000/mm³ on 2 or more occasions. In patients with known or suspected immunodeficiency, physicians should consider monitoring complete blood counts if treatment continues for more than 6 weeks. Cases of severe neutropenia have been reported. These were reversible upon discontinuation of Lamisil Tablets, with or without supportive therapy. If clinical signs and symptoms suggestive of secondary infection occur, a complete blood count should be obtained. If the neutrophil count is ≤ 1000 cells/mm³, Lamisil Tablets should be discontinued and supportive management started.

Serious Skin/Hypersensitivity Reactions

There have been postmarketing reports of serious skin/hypersensitivity reactions . Manifestations of DRESS syndrome may include cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, and one or more organ complications such as hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis. If progressive skin rash or signs/symptoms of the above drug reactions occur, treatment with Lamisil Tablets should be discontinued.

Lupus Erythematosus

During postmarketing experience, precipitation and exacerbation of cutaneous and systemic lupus erythematosus have been reported in patients taking Lamisil Tablets. Lamisil Tablets should be discontinued in patients with clinical signs and symptoms suggestive of lupus erythematosus.

Laboratory Monitoring

Measurement of serum transaminases (ALT and AST) is advised for all patients before taking Lamisil Tablets.

Patient Counseling Information

See FDA-Approved Patient Labeling (PATIENT INFORMATION)

Patients taking Lamisil Tablets should receive the following information and instructions:

  • Advise patients to immediately report to their physician or get emergency help if they experience any of the following symptoms: hives, mouth sores, blistering and peeling of skin, swelling of face, lips, tongue, or throat, difficulty swallowing or breathing. Lamisil Tablets treatment should be discontinued.
  • Advise patients to immediately report to their physician any symptoms of persistent nausea, anorexia, fatigue, vomiting, right upper abdominal pain, jaundice, dark urine, or pale stools. Lamisil Tablets treatment should be discontinued.
  • Advise patients to report to their physician any signs of taste disturbance, smell disturbance and/or depressive symptoms, fever, skin eruption, lymph node enlargement, erythema, scaling, loss of pigment, and unusual photosensitivity that can result in a rash. Lamisil Tablets treatment should be discontinued.
  • Advise patients to minimize exposure to natural and artificial sunlight (tanning beds or UVA/B treatment) while using Lamisil Tablets.
  • Advise patients that if they forget to take Lamisil Tablets, to take their tablets as soon as they remember, unless it is less than 4 hours before the next dose is due. Advise patients to call their physician if they take too many Lamisil Tablets.

Nonclinical Toxicology

Carcinogenesis, Mutagenesis, Impairment Of Fertility

In a 28-month oral carcinogenicity study in rats, an increase in the incidence of liver tumors was observed in males at the highest dose tested, 69 mg/kg/day (2x the MRHD based on AUC comparisons of the parent terbinafine); however, even though dose-limiting toxicity was not achieved at the highest tested dose, higher doses were not tested.

The results of a variety of in vitro (mutations in E. coli and S. typhimurium, DNA repair in rat hepatocytes, mutagenicity in Chinese hamster fibroblasts, chromosome aberration, and sister chromatid exchanges in Chinese hamster lung cells), and in vivo (chromosome aberration in Chinese hamsters, micronucleus test in mice) genotoxicity tests gave no evidence of a mutagenic or clastogenic potential.

Oral reproduction studies in rats at doses up to 300 mg/kg/day (approximately 12x the MRHD based on BSA comparisons) did not reveal any specific effects on fertility or other reproductive parameters. Intravaginal application of terbinafine hydrochloride at 150 mg/day in pregnant rabbits did not increase the incidence of abortions or premature deliveries nor affect fetal parameters.

Use In Specific Populations

Pregnancy

Pregnancy Category B

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because treatment of onychomycosis can be postponed until after pregnancy is completed, it is recommended that Lamisil Tablets not be initiated during pregnancy.

Oral reproduction studies have been performed in rabbits and rats at doses up to 300 mg/kg/day and have revealed no evidence of impaired fertility or harm to the fetus due to terbinafine.

Nursing Mothers

After oral administration, terbinafine is present in breast milk of nursing mothers. The ratio of terbinafine in milk to plasma is 7:1. Treatment with Lamisil Tablets is not recommended in women who are nursing.

Pediatric Use

The safety and efficacy of Lamisil Tablets have not been established in pediatric patients with onychomycosis.

Geriatric Use

Clinical studies of Lamisil Tablets did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Renal Impairment

In patients with renal impairment (creatinine clearance less than or equal to 50 mL/min) the use of Lamisil Tablets has not been adequately studied.

To help counsel patients, pharmacists can focus on fungal skin infections that are amenable to self-treatment with OTC antifungals.
Pharmacists are likely to encounter patients seeking advice about the various nonprescription topical antifungals currently on the market.
These products are formulated to relieve the itching, burning, cracking, and scaling of skin that are often associated with fungal skin infections such as tinea pedis, tinea corporis, and tinea cruris (Online Table 1).1

Active Ingredient Indications Examples of Products
Clotrimazole and miconazole nitrate Indicated for treating tinea pedis, tinea cruris, and tinea corporis; typically applied twice a day for up to 4 wk; improvement may be observed after 2 wk of use; rare cases of mild burning and skin irritation have been reported
  • Lotrimin AF (clotrimazole)
  • Micatin (miconazole nitrate)
  • Desenex antifungal (miconazole nitrate)
Terbinafine hydrochloride Indicated for treating interdigital tinea pedis, tinea cruris, and tinea corporis caused by Epidermophyton floccosum, Trychophyton mentagrophytes, and Trychophyton rubrum; typically applied to affected area twice daily; common adverse effects include skin irritation, burning, and dryness
  • Lamisil AT Antifungal Gel
  • Lamisil AT cream or spray
Tolnaftate The only nonprescription agent approved for both preventing and treating tinea infections; applied to affected area twice daily after the affected area is cleaned thoroughly; effective therapy usually takes 2-4 wk, although 4-6 wk may be required in some individuals
  • Tinactin cream
  • Tinactin Powder Spray
  • Lamisil Defense Athlete’s Foot Spray Powder
Butenafine hydrochloride Indicated for treating tinea pedis between toes, tinea cruris, and tinea corporis caused by E floccosum, T mentagrophytes, and T rubrum; Applied twice daily for 4 wk or as directed by primary health care provider for interdigital tinea pedis; for tinea cruris or tinea corporis, apply once a day for 2 wk or as directed by primary health care provider
  • Lotrimin Ultra Cream

Dermatomycoses, also referred to as fungal skin infections, are frequently occurring cutaneous disorders.1,2 Typically, these fungal infections are superficial and can involve the hair, nails, and skin.1,2 The most prevalent fungal skin infection in humans is tinea pedis, which is commonly known as athlete’s foot.1 Onychomycosis, or tinea unguium, affects the nails and may also occur in conjunction with tinea pedis.1-5 The other commonly occurring fungal skin infections include tinea corporis (ringworm of the body) and tinea capitis (ringworm of the scalp), which are most prevalent among the prepubescent patient population, and tinea cruris (jock itch), which is most common among adult males.1-5
While the signs and symptoms of these infections may vary in severity among individuals, most cases can be easily managed with proper treatment. Self-treatment of onychomycosis with topical nonprescription antifungals is not approved by the FDA; recommended treatment for this type of infection involves the use of prescription systemic agents or surgical removal of the affected area.1,2 Like onychomycosis, tinea capitis cannot be successfully managed with the use of topical nonprescription antifungals.1 This article focuses on fungal skin infections that are amendable to self-treatment with the use of currently available topical nonprescription antifungals.
The goals of treating antifungal skin infections are to provide the patient with symptomatic relief, successfully eliminate infection, and prevent recurrence of infections.1
Nonprescription Topical Antifungals
Most cases of tinea pedis, tinea corporis, and tinea cruris can be successfully self-treated with nonprescription topical antifungals in conjunction with various nonpharmacologic measures. Available nonprescription topical antifungal agents include butenafine hydrochloride, clotrimazole, miconazole nitrate, terbinafine hydrochloride, and tolnaftate, which are considered safe and effective for treating mild to moderate fungal skin infections.1 These products are available in dosage forms such as ointments, solutions, lotions, creams, powders, and aerosols. Various topical nonprescription products are also available to improve the appearance of nails during prescription therapy for onychomycosis. These products may decrease nail discoloration and smooth out thick or rough nails.1
Patients should discuss the use of fungal nail treatments with their primary health care provider prior to use. According to the Handbook of Nonprescription Drugs, cream and solution dosage formulations are considered to be the most effective and efficient dosage forms for delivery of agent to the epidermis, while sprays and powders are considered to be less effective because they are often not rubbed into the skin.1 Sprays and powders are considered to be useful in conjunction with creams and solutions or as preventive agents for new or recurring infections.1
Closing Thoughts
Prior to recommending any topical antifungal medication, pharmacists should ascertain whether self-treatment is appropriate and refer patients to their primary health care provider when warranted. Patients with diabetes or circulatory problems or who are immunocompromised should be referred to their primary health care provider prior to using any of these products.1 The patient’s medical/allergy history and medication profile should be screened for potential contraindications.
During counseling, patients should be advised about the proper use of these products and reminded to adhere to the recommended duration of therapy, which is typically 2 to 4 weeks unless otherwise directed. To achieve optimal therapeutic effect and eradication of tinea infections, patient adherence is critical. In addition, pharmacists can provide patients with information about various nonpharmacologic measures to prevent or decrease the incidence of recurring infections and to prevent transmission of these infections to others (Table 2). Because recurring infections may be a sign of undiagnosed diabetes, immune system disorder, or other medical problem, affected patients should be referred to their primary health care provider.1,2
Ms. Terrie is a clinical pharmacy writer based in Haymarket, Virginia.

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *